PROKINASE

Acute myocardial infarction,Pulmonary thromboembolism,Arteriovenous occlusions

Intravenous Acute myocardial infarction Adult: 1.5 million units as a single dose infused over 1 hr immediately after onset of symptoms.  Intravenous Pulmonary thromboembolism Adult: Loading dose: 250,000 units infused over 30 min. Maintenance: 100,000 units/hr for 24-72 hr depending on the condition to be treated. For cerebral retinal thrombosis, 12 hr may be sufficient. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values. Child: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values. Intravenous Arteriovenous occlusions Adult: Loading dose: 250,000 units infused over 30 min. Maintenance: 100,000 units/hr for 24-72 hr depending on the condition to be treated. For cerebral retinal thrombosis, 12 hr may be sufficient. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values. Child: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.

Severe hypertension, recent stroke, cerebral neoplasm, recent history of peptic ulcer disease, ulcerative colitis, pancreatitis, subacute bacterial endocarditis, coagulation defects also due to liver or kidney disease, recent surgery, childbirth. Hypersen

Severe hypertension, recent stroke, cerebral neoplasm, recent history of peptic ulcer disease, ulcerative colitis, pancreatitis, subacute bacterial endocarditis, coagulation defects also due to liver or kidney disease, recent surgery, childbirth. Hypersen

Fever, chills, back pain, abdominal pain, nausea, vomiting, arrhythmia, bruising, rash, pruritus, acute renal failure due to embolism and haemorrhage. Cerebral, peripheral and pulmonary embolism. Allergic reactions, liver enzyme abnormalities, hypotension. Potentially Fatal: Haemorrhage; anaphylactic shock.

Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid. Potentially Fatal: Anticoagulants, heparin, antiplatelet agents e.g. aspirin and dipyridamole affect platelet function increasing the risk of haemorrhage.

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Intravenous: Store unopened vials at room temperature. Reconstituted solutions should be kept in the refrigerator and used within 24 hr after preparation.

Streptokinase forms a complex with plasminogen which then converts plasminogen to plasmin. Plasmin breaks down clots as well as fibrinogen and other plasma proteins. Absorption: Rapidly cleared from the circulation after IV use. Excretion: Elimination half-life of streptokinase-activator complex: 23 minutes.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AD01 - streptokinase; Belongs to the class of enzymes. Used in the treatment of thrombosis.

*streptokinase information: Note that there are some more drugs interacting with streptokinase streptokinase streptokinase brands available in India Always prescribe with Generic Name : streptokinase, formulation, and dose (along with brand name if required)